Aim of the study is to verify the efficacy and safety of convalescent hyperimmune plasma infusion in hospitalized covid-19 patients non in ITU with pneumonia and respiratory symptoms within seven days from the beginning of symptoms. Efficacy is evaluated by the number of patients who will improve their clinical condition and will not be admitted to ITU. .Safety is considered in relation to adverse reactions to plasma infusion.
Biological: immune plasma
immune covid 19 plasma infusion
Inclusion Criteria:
- > 18 years
- hospitalized patients with positive covid-19 swab with respiratory symptoms and CT
confirmation of covid-19 chest disease admitted to non ITU recovery area.
- informed consent for plasma infusion
- informed consent to blood samples storing for future studies.
Exclusion Criteria:
- pregnant or breastfeeding female patient or planning for a pregnancy in the period of
the study
- immunoglobulin infusion in the last month
contraindication to transfusion or previous adverse reaction
Ospedale delle Apuane
Massa, Toscana, Italy
Investigator: mirko lombardi
Contact: +393478546332
mirkolombardi9@gmail.com
Investigator: Antonella Vincenti
mirko lombardi
00393478546332
mirkolombardi9@gmail.com
antonella vincenti
003905854931
antonella.vincenti@uslnordovest.toscana.it
antonella vincenti, Principal Investigator
ospedale delle Apuane